In secondary analysis, fetal ASM exposure-dependent effects were seen for executive function at age 4.5 years<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, May 29, 2024 (HealthDay News) — There are no differences in creative thinking at age 4.5 years for children of women with epilepsy (WWE) and children of healthy women (HW), but fetal antiseizure medication (ASM) exposure-dependent effects are seen for executive function in children of WWE, according to a study published online May 29 in Neurology<\/em>.<\/p>\n Kimford J. Meador, M.D., from Stanford University in Palo Alto, California, and colleagues examined fetal exposure of newer ASMs on creativity and executive functions in 4.5-year-old children of WWE compared with children of HW. The primary analysis included 251 and 73 children of WWE and HW, respectively.<\/p>\n The researchers observed no differences between children of WWE and HW in creativity or executive function. For creativity measures, no ASM exposure-dependent effects were seen, but there were exposure-dependent effects noted for executive function for ratio ASM concentration and ratio defined daily dose.<\/p>\n “Our findings highlight that even for epilepsy medications that are generally considered to be safe in pregnancy, dose adjustments should be made with a goal of reaching an optimal balance between controlling seizures and the minimizing negative effects on the developing child,” Meador said in a statement.<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n